{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:04:17Z","timestamp":1780398257578,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007374","name":"Universidade Federal De Minas Gerais","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007374","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Differentiated thyroid carcinoma (DTC) is the most common thyroid malignancy, with incidences increasing globally. Radioisotopic therapy with iodine-131 (RAI) is recommended after total thyroidectomy for patients at intermediate\/high risk. A new approach that involves the use of recombinant human TSH (rhTSH) to stimulate iodine-131 uptake during RAI has long been approved. In the standard protocol, 0.9\u00a0mg of rhTSH is administered intramuscularly on two consecutive days, followed by a therapeutic dose of iodine-131 on day 3. Unlike the traditional method of levothyroxine (LT4) withdrawal, this protocol allows the continuation of LT4, avoiding the symptoms and metabolic consequences of profound hypothyroidism. However, its high cost remains an important limitation in our setting. Therefore, this study evaluated whether a single intramuscular dose (0.9\u00a0mg) of rhTSH, instead of the currently recommended two doses, is sufficient to achieve the target thyroid-stimulating hormone (TSH) level (&gt;\u200930 mIU\/L) currently recommended for RAI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, cross-sectional study included 88 patients. The TSH level on day 1 (TSH D1), defined as the primary outcome, was evaluated in relation to sex, age, body weight, recurrence risk (ATA 2025), baseline TSH values, and the interval between TSH measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A single rhTSH dose substantially increased TSH levels to &gt;\u200930 mIU\/L in all patients. Age and body weight were independently associated with TSH D1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These preliminary results support the potential of single-dose rhTSH as a cost-effective and clinically feasible alternative in selected patients with DTC to achieve TSH levels\u2009&gt;\u200930 mIU\/L. Future comparative clinical trials should assess iodine uptake, therapeutic response, and long-term oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04671-y","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:08:23Z","timestamp":1780394903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single 0.9-mg intramuscular rhTSH dose achieves target TSH levels in differentiated thyroid carcinoma"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4563-6176","authenticated-orcid":false,"given":"Pedro Henrique Furst","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-4002","authenticated-orcid":false,"given":"Magda Carvalho","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2125-7051","authenticated-orcid":false,"given":"Gustavo Cancela","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"4671_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"M.D. Ringel, J.A. Sosa, Z. Baloch, L. Bischoff, G. Bloom, G.A. Brent, P.L. Brock, R. Chou, R.R. Flavell, W. Goldner, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 35, 841\u2013985 (2025). https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"},{"key":"4671_CR2","volume-title":"NCCN Guidelines Thyroid Carcinoma. Version 1","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network, NCCN Guidelines Thyroid Carcinoma. Version 1 (NCCN, Pennsylvania, 2025)"},{"key":"4671_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1210\/en.2008-1437","volume":"150","author":"A Bizhanova","year":"2009","unstructured":"A. Bizhanova, P. Kopp, Minireview: the sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. Endocrinology. 150, 1084\u20131090 (2009). https:\/\/doi.org\/10.1210\/en.2008-1437","journal-title":"Endocrinology"},{"key":"4671_CR4","first-page":"278","volume-title":"Endocrine Tumors","author":"EL Mazzaferri","year":"1993","unstructured":"E.L. Mazzaferri, Thyroid carcinoma: papillary and follicular, in Endocrine Tumors, ed. by E.L. Mazzaferri, N. Samaan (Blackwell Scientific, Cambridge, 1993), pp. 278\u2013333"},{"key":"4671_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1259\/0007-1285-50-599-799","volume":"50","author":"CJ Edmonds","year":"1977","unstructured":"C.J. Edmonds, S. Hayes, J.C. Kermode, B.D. Thompson, Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br. J. Radiol. 50, 799\u2013807 (1977). https:\/\/doi.org\/10.1259\/0007-1285-50-599-799","journal-title":"Br. J. Radiol."},{"key":"4671_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1210\/jcem.74.5.1569160","volume":"74","author":"LE Braverman","year":"1992","unstructured":"L.E. Braverman, B.M. Pratt, S. Ebner, C. Longcope, Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J. Clin. Endocrinol. Metab. 74, 1135\u20131139 (1992). https:\/\/doi.org\/10.1210\/jcem.74.5.1569160","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4671_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/nbt0993-1014","volume":"11","author":"ES Cole","year":"1993","unstructured":"E.S. Cole, K. Lee, K. Lauziere, C. Kelton, S. Chappel, B. Weintraub, D. Ferrara, P. Peterson, R. Bernasconi, T. Edmunds, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology. 11, 1014\u20131024 (1993). https:\/\/doi.org\/10.1038\/nbt0993-1014","journal-title":"Biotechnology"},{"key":"4671_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1210\/jc.78.1.188","volume":"78","author":"CA Meier","year":"1994","unstructured":"C.A. Meier, L.E. Braverman, S.A. Ebner, I. Veronikis, G.H. Daniels, D.S. Ross, D.J. Deraska, T.F. Davies, M. Valentine, L.J. DeGroot, Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I\/II study). J. Clin. Endocrinol. Metab. 78, 188\u2013196 (1994). https:\/\/doi.org\/10.1210\/jc.78.1.188","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4671_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/nejm199709253371304","volume":"337","author":"PW Ladenson","year":"1997","unstructured":"P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri, F. Brucker-Davis, D.S. Cooper, J.R. Garber, F.E. Wondisford, T.F. Davies, L.J. DeGroot, G.H. Daniels, et al. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma. N Engl. J. Med. 337, 888\u2013896 (1997). https:\/\/doi.org\/10.1056\/nejm199709253371304","journal-title":"N Engl. J. Med."},{"key":"4671_CR10","first-page":"1222473","volume":"14","author":"J Xiao","year":"2023","unstructured":"J. Xiao, Y. Shen, Y. Zhang et al., A pre-ablation serum TSH value between 30 and 70 mIU\/L may predict better long-term outcomes in DTC after RAI. Front. Endocrinol. 14, 1222473 (2023)","journal-title":"Front. Endocrinol."},{"key":"4671_CR11","doi-asserted-by":"publisher","first-page":"e220219","DOI":"10.1530\/etj-22-0219","volume":"12","author":"N Ju","year":"2023","unstructured":"N. Ju, L. Hou, H. Song, Z. Qiu, Y. Wang, Z. Sun, Q. Luo, C. Shen, TSH\u2009\u2265\u200930 mU\/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer. Eur. Thyroid J. 12, e220219 (2023). https:\/\/doi.org\/10.1530\/etj-22-0219","journal-title":"Eur. Thyroid J."},{"key":"4671_CR12","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1210\/jc.2005-0534","volume":"90","author":"MG Castagna","year":"2005","unstructured":"M.G. Castagna, A. Pinchera, A. Marsili, M. Giannetti, E. Molinaro, P. Fierabracci, L. Grasso, F. Pacini, F. Santini, R. Elisei, Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 4047\u20134050 (2005). https:\/\/doi.org\/10.1210\/jc.2005-0534","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4671_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/mnm.0b013e32804c58c2","volume":"28","author":"P Zanotti-Fregonara","year":"2007","unstructured":"P. Zanotti-Fregonara, F. Duron, I. Keller, A. Khoury, J.Y. Devaux, E. Hindi\u00e9, Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. Nucl. Med. Commun. 28, 257\u2013259 (2007). https:\/\/doi.org\/10.1097\/mnm.0b013e32804c58c2","journal-title":"Nucl. Med. Commun."},{"key":"4671_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1210\/jc.2002-020953","volume":"88","author":"G Vitale","year":"2003","unstructured":"G. Vitale, G.A. Lupoli, A. Ciccarelli, A. Lucariello, M.R. Fittipaldi, F. Fonderico, A. Panico, G. Lupoli, Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J. Clin. Endocrinol. Metab. 88, 1319\u20131322 (2003). https:\/\/doi.org\/10.1210\/jc.2002-020953","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4671_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s13139-015-0348-y","volume":"49","author":"SH Son","year":"2015","unstructured":"S.H. Son, S.W. Lee, J.H. Jung, C.Y. Kim, D.H. Kim, S.Y. Jeong, B.C. Ahn, J. Lee, Analysis of clinical factors for the determination of optimal serum level of thyrotropin after recombinant human thyroid-stimulating hormone administration. Nucl. Med. Mol. Imaging. 49, 268\u2013275 (2015). https:\/\/doi.org\/10.1007\/s13139-015-0348-y","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"4671_CR16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1089\/thy.2010.0177","volume":"20","author":"R Over","year":"2010","unstructured":"R. Over, H. Nsouli-Maktabi, K.D. Burman, J. Jonklaas, Age modifies the response to recombinant human thyrotropin. Thyroid. 20, 1377\u20131384 (2010). https:\/\/doi.org\/10.1089\/thy.2010.0177","journal-title":"Thyroid"},{"key":"4671_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.biopha.2007.04.001","volume":"61","author":"T Montesano","year":"2007","unstructured":"T. Montesano, C. Durante, M. Attard, U. Crocetti, D. Meringolo, R. Bruno, S. Tumino, D. Rubello, A. Al-Nahhas, M. Colandrea, et al., Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed. Pharmacother. 61, 468\u2013471 (2007). https:\/\/doi.org\/10.1016\/j.biopha.2007.04.001","journal-title":"Biomed. Pharmacother"},{"key":"4671_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1089\/thy.2012.0284","volume":"23","author":"H Hautzel","year":"2013","unstructured":"H. Hautzel, E. Pisar, D. Lindner, M. Schott, R. Grandt, H.W. M\u00fcller, Impact of renal function and demographic\/anthropomorphic variables on peak thyrotropin after recombinant human thyrotropin stimulation: a stepwise forward multiple-regression analysis. Thyroid. 23, 662\u2013670 (2013). https:\/\/doi.org\/10.1089\/thy.2012.0284","journal-title":"Thyroid"},{"issue":"10","key":"4671_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-003-1277-6","volume":"30","author":"M Luster","year":"2003","unstructured":"M. Luster, S. Sherman, M. Skarulis, Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 30(10), 1371\u20131377 (2003). https:\/\/doi.org\/10.1007\/s00259-003-1277-6","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"4671_CR20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.2967\/jnumed.110.081174","volume":"52","author":"M Ora","year":"2011","unstructured":"M. Ora, P. Madhusudanan, S. Jain, S. Barai, S. Gambhir, The need for a low-expense universally acceptable rhTSH protocol. J. Nucl. Med. 52, 1166\u20131166 (2011). https:\/\/doi.org\/10.2967\/jnumed.110.081174","journal-title":"J. Nucl. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04671-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:08:24Z","timestamp":1780394904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04671-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4671"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04671-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Hospital Orizonti (protocol number CAAE 61747522.0.0000.0151).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All participants provided written informed consent authorizing additional venipuncture for TSH D1 measurements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of their anonymized data presented in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"202"}}